ABSTRACT
BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization on 11th March 2020. The treatment guidelines for COVID-19 vary between countries, yet there is no approved treatment to date. AIM: To report any evidence of therapeutics used for the management of patients with COVID-19 in clinical practice since emergence of the virus. METHODS: A systematic review protocol was developed based on the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English published from 1st December 2019 to 26th March 2020 were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the types of study eligible for inclusion. RESULTS: Four hundred and forty-nine articles were identified in the literature search; of these, 41 studies were included in this review. These were clinical trials (N=3), case reports (N=7), case series (N=10), and retrospective (N=11) and prospective (N=10) observational studies. Thirty-six studies were conducted in China (88%). Corticosteroid treatment was reported most frequently (N=25), followed by lopinavir (N=21) and oseltamivir (N=16). CONCLUSIONS: This is the first systematic review to date related to medication used to treat patients with COVID-19. Only 41 studies were eligible for inclusion, most of which were conducted in China. Corticosteroid treatment was reported most frequently in the literature.
ABSTRACT
INTRODUCTION: This multi-site study evaluated two breath-hold sequences commonly utilised for liver MRI; non-enhanced T1W-3D-FS-GRE-TRA and T2W-2D-FSE-TRA sequences, using physical measurements of SNR and CNR, and observer perceptions' (Visual Grading Analysis: VGA). METHODS: Liver MR image datasets (n = 168) from nine hospitals in the Kingdom of Saudi Arabia (KSA) and 11 hospitals in the Republic of Ireland were evaluated. Images were categorised into two groups per sequence, defined by slice thickness (T2W-2D-FSE, ≤5 mm vs ≥ 6 mm and T1W-3D-GRE-FS, ≤3 mm vs 4 mm). Images were evaluated using visual grading analysis VGA and physical measurements: SNR/CNR. Account was taken of varying patient sizes based on AP/transverse diameter measurements. RESULTS: Physical image quality measurements (SNR/CNR) returned no significant findings across Irish and KSA hospitals, for both sequences, despite variations in acquisition parameters. Statistically significant differences were found for some scoring criteria based on the observers' perceptions including spleen parenchyma, and spatial resolution for the non-enhanced T1W-3D-FS-GRE-TRA images, with a preference for images acquired using thin slices (≤3 mm). In addition, statistically significant difference was found for the scoring criteria motion artefact for the axial T2W-2D-FSE-TRA images, with a preference for images acquired using thick slices (≥5 mm). Negligible correlation was noted between SNR/CNR and measured abdominal AP/transverse diameters. CONCLUSION: Whilst variations in sequences rendered no statistical differences in SNR/CNR findings, significant differences in observer image criteria scores was noted. The importance of both physical measurements and observers' perceptions evaluation methods for quality assessment of MR images was demonstrated and optimisation of liver sequence parameters is warranted.
